

1. **Adı Soyadı** : Kemal YELEKÇİ
2. **Ünvanı** : Prof. Dr.
3. **Öğrenim Durumu** : Doktora



Derece	Alan	Üniversite	Yıl
Lisans	Kimya	Orta Doğu Teknik Üniversitesi	1979
Y. Lisans	Organik Kimya	Çukurova Üniversitesi	1981
Doktora	Organik Kimya	Ohio Üniversitesi	1987
Doktora Sonrası	Medsinal Kimya	Northwestern Üniversitesi	1988

4. Akademik Ünvanlar

- Yardımcı Doçentlik Tarihi** : Eylül 1988
Doçentlik Tarihi : Ekim 1989
Profesörlük Tarihi : Şubat 1996

ARAŞTIRMA ALANLARI: İlaç tasarımı ve ilaç etkisi ile ilgili araştırma ve geliştirilme. Organik sentez, enzimlere tasarlanan küçük ilaç molekülleri, reseptör ligand etkileşimleri ve transport protein mekanizmalarının incelenmesi. Bilgisayar destekli ilaç tasarımı. İn siliko ilaç adayları taraması, serbest enerji hesaplamaları, protein-substrat kompleks yapılarının dinamik davranışlarının incelenmesi konuları esas olarak çalıştığım konulardır. Monoamin oksidaz (A ve B), Nitrik oksit sentez, gibi depresyon, Parkinson ve nörodejenerasyon ile ilgili enzim mekanizmaları ve bu enzimlere tasarlanan etkisi ve seçiciliği yüksek ilaçlar. Parkinson ve Alzheimer gibi nörodejeneratif hastalıklarla ilgili Dopamin transporterinin incelenmesi ve anlaşılmasına yönelik çalışmalar. Antikanser ilaç hedefleri olan epigenetik modifikasyon yapan Histon Deasetilaz enzimleri (1,3,4,5, 6,8) ile ilgili araştırmalar. Prostat kanseri ile ilgili olduğu düşünülen Metionine amino peptidaz (MetAP2) enzimine yönelik ilaç tasarımı ve geliştirilmesi.

5. Yönetilen Yüksek Lisans ve Doktora Tezleri

5.1. Yüksek Lisans Tezleri

- 5.1.1. M. VEZİR KAHRAMAN 1995 M. S. Synthesis of α -(2-aminomethyl)-N-phenyl nitrene
- 5.1.2. DİLBER DAMAR 2001 M. S. Synthesis of Ethyl-2-nitro-3-hydroxy-3-(3,4-dimethoxyphenyl) propanoate.
- 5.1.3. GÜL ALTINBAŞ 2001 M. S. Investigation of the Friedel Crafts acylation of toluene with various substrates.
- 5.1.4. İBRAHİM YILDIZ 2003 M. S. Computationally investigation of addition-elimination reaction mechanism of monoamine oxidase (MAO) enzyme.
- 5.1.5. ÖZLEM KARAHAN 2004 M. S. Computationally investigation of oxidation reaction mechanism of monoamine oxidase (MAO) enzyme.
- 5.1.6. ÇAĞLA MIDİK 2012 M. S. In silico inhibitor design for monoamine oxidase A and B isozymes
- 5.1.7. ERÇİN DİNÇER 2012 M. S. Structure prediction of TB rPOB and its mutations binding analysis
- 5.1.8. FİLİZ VARNALI 2012 M. S. Designing inhibitors via molecular modelling methods for monoamine oxidase isozymes A and B
- 5.1.9. SERKAN ALTUNTAŞ 2013 M. S. In silico design of selective monoamine oxidase B inhibitors using indane ring
- 5.1.10. BORA BÜYÜKTÜRK 2013 M. S. De novo selective inhibitor design to neuronal NOS enzyme and exploration of the binding site
- 5.1.11. NURDAN KAYRAK 2013 M. S. In silico design of selective neuronal nitric oxide synthase
- 5.1.12. TALHA KARABIYIK 2014 M. S. In silico identification of physiological substrates and inhibitors of serum paraoxonase 1 enzyme
- 5.1.13. TUĞBA MEHMETOĞLU 2014 M. S. In silico design of novel and highly selective cyclooxygenase-2 inhibitors
- 5.1.14. BAHANUR ÖRTMEN 2014 M. S. In silico screening of neuronal nitric oxide synthase enzyme inhibitors
- 5.1.15. DİLARA KARAMAN 2014 M. S. In silico design and modeling of coumarin derivatives as selective monoamine oxidase inhibitors
- 5.1.16. FATMA M.AB. ALNEMSI 2016 M. S. Docking study of sesveratrol like molecules on histone deacetylase 8
- 5.1.17. SİNAN FINDIK 2016 M. S. Exploring the action mechanism of amphipathic α -Helical Antimicrobial Peptides, L1-23 And Its Single-Nucleotide Variants Via Computational Methods

- 5.1.18.** JACKSON WEAKO 2017 M. S. In silico screening of tangible-potential inhibitor of methionine aminopeptidase 2 for the treatment of cancer
- 5.1.19.** SEDAT TANJU KARADENİZ 2017 M. S. Corrected PRA positivity rates for hypersensitized patients in Turkish population with calculated PRA-cPRA software
- 5.1.20.** AUGUSTINE S. SAMORLU 2018 M. S. In silico screening of potent HIV-1 integrase inhibitors for the treatment of human immunodeficiency virus (HIV).
- 5.1.21.** Safanah Albayati. M. S., “Selective and Potent Inhibitors Design for Methionine Aminopeptidase II (MetAPs II) using Pharmacophore Modeling” (2019).
- 5.1.22.** Şafak Naz Şentürk, M. S., “Peptidomimetic drug candidates for methionine amino peptidase II enzyme for prevention of cancer”. (2019).
- 5.1.23.** Sarah Raji, Developing Dual inhibitors for Monoamine Oxidase B and Acetylcholine Esterase Enzyme for Neuroprotection, 2019.
- 5.1.24.** Marwah Abd Alı N.Al-Shafeay Selective Inhibitor Design for Lysine Demethylase 1 (LSD1), Enzyme Using Molecular Modeling Techniques, 2019.
- 5.1.25.** Anas Abdulqader Abbas Al-Obaidi, M.S., “Development of Novel and Potent Inhibitors For GABA-AT Enzyme Via In Silico Screening Methods”, 2020.
- 5.1.26.** Farah Ismael Abduljabbar Abduljabbar, In silico Screening of Potential Agonist for Peroxisome Proliferator Activated Receptor (PPARa/b) to Treat Diabetes Miletus 2020.
- 5.1.27.** Maryam Muhsin Taher Al-Rikabi Molecular modeling of cyclopropyl amine derivatives as inhibitors of lysine specific demethylase 1 (LSD1), 2020.
- 5.1.28.** Naz Mina Mert, Designing of selective and potent inhibitors against histone deacetylase enzymes (HDAC6 and HDAC10) via *in silico* screening and molecular modeling techniques for treatment of cancer, 2021.
- 5.1.29.** Gamze Çiftci, Design of Novel and Potent Inhibitors for mPGES-1 Enzyme via In Silico Screening, 2021.
- 5.1.30.** Meltem Yıldırım

6. Doktora Tezleri

- 6.1.1.** M. VEZİR KAHRAMAN Ph. D. Synthesis of biologically active amino ethers (2001).
- 6.1.2.** SEVİM KARATAŞ 2001 Ph. D Synthesis of ethyl α -3,4-halo-disubstituted cinnamate and α -acylamino 3,4-disubstituted cinnamic acid and reduction product on Pd/C (2001).

- 6.1.3. TEODORA DIJKIC Ph. D. In silico modeling of dopamine transporter and design of novel neuroprotective drugs for Parkinson's disease (2017).
- 6.1.4. ABDULLAHİ İBRAHİM UBA. 2018 Ph.D. Targeting cancer epigenetic modifiers: The design of isoform-selective histone deacetylase inhibitors (2018).
- 6.1.5. Ammar Almezayan, Ph. D. “In Silico Designing of Isoform-Selective Inhibitors Against Class IIa Histone Deacetylases”, (2021).
- 6.1.6. Sedat Tanju Karadeniz, Ph. D., “Augmented Virtual-Cross-Match for Donor-Induced Antibody Prediction by Using High Resolution HLA Typing and HLA Epitope Mapping for Better Donor Match”, (2021).
- 6.1.7. Sarah Boumezber, Ph. D., “Designing of Selective and Potential of Neuronal Nitric Oxide Synthase Inhibitors Toward the Prevention Neurodegenerative Disease Using in Silico Screening Methods”, (2021).

7. Yayınlar

7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI,SSCI,Arts and Humanities)

- 7.1.1. K.Yelekçi; M.Acımış; H.Soran. “Melia azedarach L. Meyvelerinden Çıkarılan Özütlerin Çam Keseböceği Tırtıllarına Etkisi “, *Doğa Bilim Dergisi, Temel Bilim. Cilt 5, 1981, 69-71.*
- 7.1.2. K.Yelekçi; H.Evliya.“Melia azedarach L. Meyvelerinden İzole edilen 7-Tricosanol’in Tanımlanması”*Doğa Bilim Dergisi, Temel Bilim. Cilt 6, 1982, 45-51.*
- 7.1.3. W.D.Huntsman; J.P.Chen; K.Yelekçi; T.K.Yin; L.J.Zhang“Thermal Aromatization of Alkylidenecyclopentenes and Related Hydrocarbons “*J. Org. Chem.1988,53,4357-4363.*
- 7.1.4. K.Yelekçi; X.Lu; R.B.Silverman, “Electron Spin resonance Studies of Monoamine Oxidase B. First Direct Evidence for a Substrate Radical Intermediate”, *J. Am.Chem.Soc. 1989,111,1338-1340.*
- 7.1.5. K.Yelekçi, “Synthesis of 1-Aminocyclobutane Derivates”*Turkish, J.Chem. 1992, 16(1), 18-28.*
- 7.1.6. V.J. Drose; J.C.G. Woo; W.P.Hawe; B.M. Hoffman; R:B: Silverman; K. Yelekçi, “Observation of a Flavin Semiquinone in the Resting State of Monoamine Oxidase by Electron Paramagnetic resonance and Electron Nuclear Double Resonance”, *Biochemistry 1996, 35, 11085-11091.*
- 7.1.7. K. Yelekçi; R.B. Silverman, “Effect of the Locus of the Oxygen Atom in Amino Ethers on The Inactivation of Monoamine Oxidase B”, *J. Enzyme Inhibition. 1998, 13, 31-39.*
- 7.1.8. S. S. Erdem; K. Yelekçi, “Computer Modeling of Oxygen Containing Heptylamines as Monoamine Oxidase Inactivators” *Journal of Molecular Structure (Theochem) 572 (2001), 97-106.*

- 7.1.9.** Mustafa Toprakçı, Kemal Yelekçi, “Docking studies on Monoamine Oxidase-B inhibitors: estimation of inhibition constants (K_i) of a series of experimentally tested compounds”, *Bioorganic & Medicinal Chemistry Letters*, 15 (2005) 4438-4446.
- 7.1.10.** Safiye Sağ Erdem, Özlem Karahan, İbrahim Yıldız and Kemal Yelekçi . “A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism”, *Organic & Biomolecular Chemistry*, 2006, 4, 646-658. (Bu makale “The Royal Society of Chemistry” kapsamında uluslararası yayınlanan dergiye kapak olmuştur.)
- 7.1.11.** Kemal Yelekçi, S. Erdem, Ö. Karahan, F. Uyar, “Synthesis and Thermal Reactions of -Acetoxy-2,6,6-Trimethylbicyclo[3.1.0] hexane: Elucidation of the Mechanism of the Reaction with Coputational Approach”, *Journal of Molecular Structure: THEOCHEM*, 814 (2007) 61-73.
- 7.1.12.** Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı, “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties (ΔG and K_i)”, *Journal of Neural Transmission*, (2007) 114: 725-732.
- 7.1.13.** Yelekci K, Erdem SS , “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo[3.1.0]hexane: Theoretical elucidation of the mechanism”, *ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY* Volume: 234 Meeting Abstract: 326-COMP Published: AUG 19 2007.
- 7.1.14.** Yelekci K, Bora G, Dayangac-Erden D, et al. “COMP 297- Experimental and molecular docking simulation studies of Histone deacetylases (HDACs) enzyme inhibitors”, *ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY* Volume: 234 Meeting Abstract: 297-COMP Published: AUG 19 2007.
- 7.1.15.** Yelekci, K, Dayangac-Erden D, Ayhan P, Bora G, et al. “MEDI 333- Histone deacetylase inhibition activity of resveratrol and its analogs”, *ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY* Volume: 234 Meeting Abstract: 333-MEDI Published: AUG 19 2007.
- 7.1.16.** Nesrin Gökhan-Kelekçi, Semra Koyunoğlu, Samiye Yabanoğlu, Kemal Yelekçi, Özen Özgen, Gulberk Uçar, Kevser Erol, Engin Kendi, Akgül Yeşilada, "New Pyrazoline Bearing 4(3H)-quinazolinone Inhibitors of Monoamine Oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity”, *Bioorganic & Medicinal Chemistry*. (2009), 17(2), 675-689.
- 7.1.17.** Didem Dayangaç-Erden, Gamze Bora, Peruze Ayhan, Çetin Kocaefe, Sevim Dalkara, Kemal Yelekçi, Ayhan S. Demir, Hayat Erdem-Yurter, “Histone Deacetylase Inhibition Activity and Molecular Docking of (E)-Resveratrol: its Therapeutic Potential in Spinal

Muscular Atrophy”, *Chemical Biology & Drug Design*, (2009), 37(3), 355-364.

- 7.1.18.** Gamze Bora-Tatar, Didem Dayangaç-Erden, Ayhan S. Demir, Sevim Dalkar, Kemal Yelekçi, Hayat Erdem-Yurter, “Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies”, *Bioorganic & Medicinal Chemistry*, (2009), 17(18), 6761-6772.
- 7.1.19.** Nesrin Gökhan-Kelekçi, Ö. Özgün Şimşek, Ayşe Ercan, Kemal Yelekçi, Z. Sibel Şahin Şamil Işık, Gülberk Uçar, A. Altan Bilgin. “Synthesis and molecular modeling of some novel hexahydroindazole derivatives as “potent monoamine oxidase inhibitors”, *Bioorganic & Medicinal Chemistry* (2009), 17(4), 5219-5228.
- 7.1.20.** Ebru Demet Akdoğan, Burak Erman, Kemal Yelekçi. “In silico design of novel and highly selective lysine-specific histone demethylase inhibitors”, *Turk J Chem* 35 (2011), 523-542, (doi:10.3906/kim-1102-985).
- 7.1.21.** Gamze Bora Tatar, Tenzile Deniz Tokluman, Kemal Yelekçi, Hayat Yurter, “Power of inhibition activity screening and 3D molecular modeling approaches in HDAC 8 inhibitor design”, *Turk J Chem*, 35 (2011), 861 – 870. (doi:10.3906/kim-1107-34).
- 7.1.22.** Safiye Sağ Erdem, Seyhan Türkkkan, Kemal Yelekçi, Nesrin Gökhan-Kelekçi, “Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations”, *J Neural Transm*, (2013) 120:859–862, (DOI 10.1007/s00702-012-0950-4).
- 7.1.23.** Umut Salgın-Gökşen, Samiye Yabanoğlu-Çiftçi, Ayşe Ercan, Kemal Yelekçi, Gülberk Uçar, Nesrin Gökhan-Kelekçi, “Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives”, *J Neural Transm*, (2013) 120:863–873, (DOI 10.1007/s00702-013-0980-6).
- 7.1.24.** Umut Salgın-Gökşen, Nesrin Gökhan-Kelekçi, Samiye Yabanoğlu-Çiftçi, Kemal Yelekçi, Gülberk Uçar, “Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives”, *J Neural Transm* (2013) 120:883–891, (DOI 10.1007/s00702-013-0968-2).
- 7.1.25.** Kemal Yelekçi, Bora Büyüktürk, Nurdan Kayrak, “In silico identification of novel and selective monoamine oxidase B inhibitors”, *J Neural Transm* (2013) 120:853–858, (DOI 10.1007/s00702-012-0954-0).
- 7.1.26.** Peruze Ayhan Eşiyok, Özlem Seven, Gülüzar Eymur, Gamze Bora Tatar, Didem Dayangac Erden, Kemal Yelekçi, Hayat Yurter, Ayhan Sıtkı Demir. “Aryl butenoic acid derivatives as a new class of histone deacetylase inhibitors: synthesis, in vitro evaluation, and molecular docking studies”, *Turk J Chem*, 38 (2014), 338 – 344. (doi:10.3906/kim-1305-56).

- 7.1.27.** Begüm Evranos-Aksöz , Samiye Yabanoğlu-Çiftçi, Gülberk Uçar, Kemal Yelekçi, Rahmiye Ertan. “Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies”, *Bioorganic & Medicinal Chemistry Letters*, 24 (2014) 3278-3284. <http://dx.doi.org/10.1016/j.bmcl.2014.06.015>.
- 7.1.28.** Kemal Yelekçi, Bahanur Örtmen “De Novo Design of Potent and Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors by a Fragment-Based Approach”, *Journal of Pharmaceutical Chemistry*, 2014, 1 (4), 68-73.
- 7.1.29.** Evranos-Aksöz B, Baysal İ, Yabanoğlu-Çiftçi S, Djikic T, Yelekçi K, Uçar G, Ertan R. “Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.”. *Arch Pharm (Weinheim)*. 2015. Oct;348(10):743-56. doi: 10.1002/ardp.201500212. Epub 2015.
- 7.1.30.** F. Pinar Turkmenoglu, İpek Baysal, Samiye Ciftci-Yabanoglu, Kemal Yelekci, Hamdi Temel, Salih Paşa, Nurten Ezer, İhsan Çalış and Gulberk Ucar., “Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol.” *Molecules Journal*, 2015 Apr 23;20(5):7454-73. doi: 10.3390/molecules, 20057454.
- 7.1.31.** Katarina Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, Kemal Yelekci and John B.O. Mitchell. “Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies” <http://dx.doi.org/10.3389/fnins.2016.00265>. *Front. Neurosci.*, 10 June 2016.
- 7.1.32.** S.T. Karadeniz, S.U. Akgul, Y. Ogret, H.S. Ciftci, A. Bayraktar, H. Bakkaloglu, Y. Caliskan, K. Yelekci, A. Turkmen, A.E. Aydin, F.S. Oguz, M. Carin, and F. Aydin, “Corrected Panel-Reactive Antibody Positivity Rates for Hypersensitized Patients in Turkish Population With Calculated Panel-Reactive Antibody Software”, <http://dx.doi.org/10.1016/j.transproceed.2017.01.032>, *Transplantation Proceedings*, 49, 445e447 (2017).
- 7.1.33.** Karadeniz, Sedat Tanju; Akgul, Sabahat; Ciftci, Hayriye Senturk; Yelekci, Kemal; et al. “Epitope Based Hla Matching By Using Antibody Reactivity With High Resolution Allele Typing And Hlamatchmaker Algorithm Based Software”, *Transplant International*, 30 Special Issue: SI Supplement: 2 Pages: 302-302 Meeting Abstract, 2017.
- 7.1.34.** Evranos-Aksoz, Begum; Ucar, Gulberk; Tas, Sadik Taskin; Yelekci, Kemal; et al. “New Human Monoamine Oxidase an Inhibitors with Potential Anti-Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity”, *COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING*, 20(6) Pages: 461-473, 2017.
- 7.1.35.** Evranos-Aksoz, Begum; Ucar, Gulberk; Yelekci, Kemal

“Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues”, *COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING*, 20, Issue: 6 Pages: 510-521, **2017**.

- 7.1.36.** Abdullahi İbrahim UBA, Kemal YELEKÇİ “Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors”, *Turk J Biol* (**2017**) 41, TÜBİTAK doi:10.3906/biy-1701-26.
- 7.1.37.** Abdullahi Ibrahim Uba, Kemal Yelekçi (**2018**). Identification of potential isoform- selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. *Journal of Biomolecular Structure and Dynamics*, 36:12, 3231- 3245. doi: <http://doi.org/10.1080/07391102.2017.1384402>. (IF: 3.107)
- 7.1.38.** Abdullahi Ibrahim Uba, Kemal Yelekçi (**2018**). Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: structure-based virtual screening, molecular docking and dynamics simulation studies. *Computational Biology and Chemistry*, 75: 131-142. <https://doi.org/10.1016/j.compbiolchem.2018.05.004>. (IF: 1.412)
- 7.1.39.** Göknül Coşkun, Teodora Djikic, Taha Hayal, Nezaket Türkel, Kemal Yelekçi, Fikretin Şahin, Ş Küçükgülzel, “Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors, *Molecules* 2018, 23, 1969; **2018** doi:10.3390/molecules23081969, (IF:3.09)
- 7.1.40.** Abdullahi Ibrahim Uba, Kemal Yelekçi (**2018**). Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. *Journal of Biomolecular Structure and Dynamics*, <https://doi.org/10.1080/07391102.2018.1521747>. (IF: 3.107)
- 7.1.41.** Augustine S. Samorlu, Kemal Yelekçi, Abdullahi Ibrahim Uba. The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation. *Journal of Biomolecular Structure and Dynamics.*, (**2018**) (IF: 3.107).
- 7.1.42.** Umut Salgin Goksen, Sevgi Sarigul, Patrick Bultinck, Wouter Herrebout, Ilknur Dogan, Kemal Yelekci, Gulberk Ucar, Nesrin Gokhan Kelekci, Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity, *Chirality*, 23 November **2018**. <https://doi.org/10.1002/chir.23027>, (IF:1.83).
- 7.1.43.** Işıl Çoruh, Özge Çevik, Kemal Yelekçi, Teodora Djikic, Ş Güniz Küçükgülzel Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitors *Archiv der Pharmazie*,3-4, 351, **2018**. <https://doi.org/10.1002/ardp.201700195> (IF:2.29).
- 7.1.44.** Uba, A. I., & Yelekçi, K. (**2018**). Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6. *Computational Biology and Chemistry*, 77, 318-330. doi:10.1016/j.compbiolchem.2018.10.016, (IF: 1.412).

- 7.1.45.** Coşkun, G. P., Djikic, T., Kalaycı, S., Yelekçi, K., Şahin, F., & Güniz Küçükgülzel, Ş. (2019). Synthesis, molecular modelling and antibacterial activity against helicobacter pylori of novel diflunisal derivatives as urease enzyme inhibitors. *Letters in Drug Design and Discovery*, 16(4), 392-400. doi:10.2174/1570180815666180627130208.
- 7.1.46.** Djikic, T., Martí, Y., Spyrakis, F., Lau, T., Benedetti, P., Davey, G., . . . Yelekci, K. (2019). Human dopamine transporter: The first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities. *Journal of Biomolecular Structure and Dynamics*, 37(2), 291-306. doi:10.1080/07391102.2018.1426044.
- 7.1.47.** Goksen, U. S., Sarigul, S., Bultinck, P., Herrebout, W., Dogan, I., Yelekci, K., . . . Gokhan Kelekci, N. (2019). Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity. *Chirality*, 31(1), 21-33. doi:10.1002/chir.23027.
- 7.1.48.** Han, M. İ., Bekçi, H., Uba, A. I., Yıldırım, Y., Karasulu, E., Cumaoğlu, A., Yelekçi, K., . . . Küçükgülzel, Ş. G. (2019). Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide–hydrazones derived from (S)-naproxen. *Archiv Der Pharmazie*, 352(6) doi:10.1002/ardp.201800365.
- 7.1.49.** Ibrahim Uba, A., & Yelekçi, K. (2019). Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. *Journal of Biomolecular Structure and Dynamics*, 37(14), 3627-3636. doi:10.1080/07391102.2018.1521747.
- 7.1.50.** Samorlu, A. S., Yelekçi, K., & Ibrahim Uba, A. (2019). The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation. *Journal of Biomolecular Structure and Dynamics*, 37(17), 4644-4650. doi:10.1080/07391102.2018.1557559.
- 7.1.51.** Uba, A. I., Weako, J., Keskin, Ö., Gürsoy, A., & Yelekçi, K. (2019). Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation. *Journal of Biomolecular Structure and Dynamics*, doi:10.1080/07391102.2019.1615989.
- 7.1.52.** Elmezayen, A. D., Al-Obaidi, A., Şahin, A. T., & Yelekçi, K. (2020). Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. *Journal of Biomolecular Structure and Dynamics*, 1-13. doi:10.1080/07391102.2020.1758791.
- 7.1.53.** Elmezayen, A. D., & Yelekçi, K. (2020). Homology modeling and in silico design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes. *Journal of Biomolecular Structure and Dynamics*, doi:10.1080/07391102.2020.1798812, (IF: 3.107).
- 7.1.54.** Erensoy, G., Ding, K., Zhan, C., Elmezayen, A., Yelekçi, K., Duracik, M., . . . Küçükgülzel, İ. (2020). Synthesis, in silico studies and

cytotoxicity evaluation of novel 1,3,4-oxadiazole derivatives designed as potential mPGES-1 inhibitors. *Journal of Research in Pharmacy*, 24(4), 436-451. doi:10.35333/jrp.2020.187.

- 7.1.55.** Uba, A. I., & Yelekçi, K. (2020). Crystallographic structure versus homology model: A case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10. *Journal of Biomolecular Structure and Dynamics*, 38(15), 4397-4406. doi:10.1080/07391102.2019.1691658, (IF: 3.107).
- 7.1.56.** Weako, J., Uba, A. I., Keskin, Ö., Gürsoy, A., & Yelekçi, K. (2020). Identification of potential inhibitors of human methionine aminopeptidase (type II) for cancer therapy: Structure-based virtual screening, ADMET prediction and molecular dynamics studies. *Computational Biology and Chemistry*, 86. doi:10.1016/j.compbiolchem. 2020.107244, (IF: 3.107).
- 7.1.57.** Kaan Birgül, Yeliz Yıldırım, H.Yeşim Karasulu, Ercüment Karasulu, Abdullah Ibrahim Uba, Kemal Yelekçi, Hatice Bekçi, Ahmet Cumaoglu, Levent Kabasakal, Özgür Yılmaz, Ş.Güniz Küçükgülzel (2020). Synthesis, Anticancer Agents and Molecular Docking of (S)-Naproxen-1, 2, 4-Triazole Derivatives, *European Journal of Medicinal Chemistry*, 208.112841, 2020. IF: 5.572. doi:10.1016/j.ejmech.2020.112841.
- 7.1.58.** Özgür Yılmaz, Burak Bayer, Hatice Bekçi, Abdullah Ibrahim Uba, Ahmet Cumaoglu, Kemal Yelekci, S Güniz Küçükgülzel (2020) Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (type II). *Medicinal Chemistry*, 16(6), 735-749, 2020. doi:10.2174/1573406415666190613162322, PMID: 31203805, IF: 2.764.
- 7.1.59.** Ammar D. Elmezayen, Kemal Yelekçi Homology modeling and in silico design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes *Journal of Biomolecular Structure and Dynamics*, 2021-11-22, DOI: 10.1080/07391102.2020.1798812.
- 7.1.60.** Anas Al-Obaidi, Ammar D. Elmezayen, Kemal Yelekçi Homology modeling of human GABA-AT and devise some novel and potent inhibitors via computer-aided drug design techniques. *Journal of Biomolecular Structure and Dynamics* 2021-07-24, DOI: 10.1080/07391102.2020.1774417
- 7.1.61.** Ammar D. Elmezayen, Anas Al-Obaidi, Kemal Yelekçi, Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular docking, and molecular dynamics simulations for cancer treatment *Journal of Molecular Graphics and Modelling*, 2021-0, DOI: 10.1016/j.jmgm.2021.107937
- 7.1.62.** Ammar D. Elmezayen, Yelekçi Kemal, Structure-based virtual screening for novel potential selective inhibitors of class IIa histone

deacetylases for cancer treatment *Computational Biology and Chemistry* 2021-06, DOI: 10.1016/j.compbiolchem.2021.107491

- 7.1.63.** Ammar D. Elmezayen, Anas Al-Obaidi, Alp Tegin Şahin, Kemal Yelekçi, Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes *Journal of Biomolecular Structure and Dynamics* 2021-05-24, DOI: 10.1080/07391102.2020.1758791
- 7.1.64.** Safana Albayati, Abdullahi Ibrahim Uba, Kemal Yelekçi, Potential inhibitors of methionine aminopeptidase type II identified via structure-based pharmacophore modeling *Molecular Diversity* 2021-04-13, DOI: 10.1007/s11030-021-10221-7.
- 7.1.65.** Umut Salgin-Goksen, Gokcen Telli, Acelya Erikci, Ezgi Dedecengiz, Banu Cahide Tel, F. Betül Kaynak, Kemal Yelekci, Gulberk Ucar, Nesrin Gokhan-Kelekci New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors, *Journal of Medicinal Chemistry*, IF:7.446
2021-02-25 | journal-article, DOI: 10.1021/acs.jmedchem.0c01504

7.2. Uluslararası diğer hakemli dergilerde yayınlanan makaleler:

- 7.2.1.** Kemal Yelekci, Bahanur Örtmen., “De Novo Design of Potent and Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors by a Fragment-Based Approach”. *Journal of Pharmaceutical Chemistry*, ISSN: 2349-5731 (2015).

7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler:

- 7.3.1.** Kemal Yelekçi, American Chemical Society 191st National Meeting, *New York*, NY April 13-18, 1986
- 7.3.2.** Kemal Yelekçi , NATO Advanced Study Institute on “Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds Oxidation Mechanism of Monoamine Oxidase.” August 27-September 7, 1989 *Çeşme, İZMİR-TURKEY*
- 7.3.3.** Kemal Yelekçi, V.Kahraman, 35th IUPAC Congress “Synthesis and Enzyme Chemistry of Amino Nitrones as Probes of a Single Electron Transfer Mechanism for Monoamin Oxidase“, 14-19 Ağustos, *İSTANBUL*, 1995.
- 7.3.4.** Kemal Yelekçi, R.B. Silverman, S. S. Erdem, “Inductive Effect of a Heteroatom Containing Heptylamine Analogues on MAO B.” 9th International Amine Oxidase Workshop, The Millennium Meeting, *Barcelona*, July 9th-12th, 2000.
- 7.3.5.** M. Toprakçı, K. Yelekçi, “Molecular Mechanics Analysis of Binding Affinities of two Putative Ligands for Monoamine Oxidase-B Enzyme.”, 10th Amine Oxidase Workshop, University of Kadir Has, 25th – 29th August, 2002 *Istanbul*, TURKEY.

- 7.3.6.** S. S. Erdem, M. V. Kahraman, K. Yelekçi, “Modeling of Monoamine Oxidase B Inactivation: The Role of Non-bonded Interactions and Stereoelectronic Effects in Enzyme Adducts.”10th Amine Oxidase Workshop, University of Kadir Has 25th – 29th August, 2002, *Istanbul, TURKEY*.
- 7.3.7.** M. Toprakçı K. Yelekçi, “Binding affinity prediction of oxygen containing heptylamines as monoamine oxidase inactivators by molecular dynamics calculations.”11th Amine Oxidase Workshop, University of St. Andrews 25th – 29th July **2004**, *Scotland*.
- 7.3.8.** Safiye S. Erdem, Ibrahim Yıldız, Özlem Karahan and Kemal Yelekçi , “A computational study on the amine oxidation mechanism of monoamine oxidase: Polar nucleophilic or radical mechanisms ”, 11th Amine Oxidase Workshop, University of St. Andrews 25th – 29th July 2004, *Scotland*.
- 7.3.9.** Kemal Yelekçi, “Binding affinity prediction of some monoamine oxidase inactivator by molecular dynamics calculations”, Chemical Physics VI, The Sixth International Conference on Chemical Physics, 15-17 October 2004, *İstanbul , Turkey*.
- 7.3.10.** Safiye S. Erdem, Özlem Karahan, Ibrahim Yıldız and Kemal Yelekçi, “The Monoamine Oxidase Catalytic Pathway: A Computational Study”, Chemical Physics VI, The Sixth International Conference on Chemical Physics, 15-17 October 2004, *İstanbul , Turkey*.
- 7.3.11.** Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites” , “12th International Amine Oxidase Workshop “, University of Erasmus, 30th July – 03th August 2006, Rotterdam, Nederland.
- 7.3.12.** Kemal Yelekçi, Mustafa Toprakçı, “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties”, 232nd ACS National Meeting, *San Francisco, CA, USA*, September 10-14, 2006.
- 7.3.13.** Kemal Yelekci, “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo [3.1.0]hexane: Theoretical elucidation of the mechanism”234th ACS National Meeting, *Boston, MA, (USA)*, August 19-23, 2007.
- 7.3.14.** G.Bora, D.Dayangaç-Erden, P.Ayhan, K.Yelekçi, S.Dalkara, A.S.Demir, H.Erdem-Yurter, “Histon deasetilaz inhibitör aktivitesinin florometrik yöntemle gösterilmesi”Tibbi Biyoloji Kongresi, 6-9 Eylül, *Antalya, TURKIYE*
- 7.3.15.** Kemal Yelekci, Gamze Bora, Didem Dayangac-Erden, Peruze Ayhan, Sevim Dalkara, Ayhan S. Demir, and Hayat Erdem-Yurter.“Experimental and molecular docking simulation studies of Histone deacetylases (HDACs) enzyme inhibitors”234th ACS National Meeting, *Boston, MA, (USA)*, August 19-23, 2007.

- 7.3.16.** Didem Dayangaç-Erden, Peruze Ayhan, Gamze Bora, Kemal Yelekçi, Sevim Dalkara, Ayhan S. Demir, Hayat Erdem-Yurteri, “Deacetylase Inhibition Activity of Resveratrol and Its Analogues”, 234th ACS National Meeting, *Boston, MA, (USA)*, August 19-23, 2007.
- 7.3.17.** Kemal Yelekçi, Nesrin Gökhan-Kelekci, Samiye Yabanoğlu, Gülberk Uçar, “Design and Biological Evaluation of New Pyrazoline Bearing 4(3H)-Quinazolinone Inhibitors of Monoamine Oxidase A and B: Binding Mode Studies Performed Through Docking Procedures” 13th International Amine Oxidase and Related Diseases Workshop, Century Huatian Hotel, *Beijing, China*, October 11 – 15, 2008
- 7.3.18.** Seyhan Türkkkan, Safiye Sağ Erdem, Kemal Yelekçi, Nesrin Gökhan Kelekçi, Umut Salgın Gökşen, Molecular Docking Of New Pyrazoline Derivatives To The Active Site Of Monoamine Oxidase, Fifth International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, 04-08 July 2009 *Istanbul - TURKEY*.
- 7.3.19.** Kemal Yelekci, “Methods and solutions for lead discovery and optimization, structure and fragment-based design, transmembrane protein analysis, and enzyme modeling”, Workshop European DS Pharmacophore Meeting, 1-3 July 2009, Romainville, *Paris, FRANCE*.
- 7.3.20.** Kemal Yelekçi, “Analysis of monoamine oxidase A and B active sites: evaluation of de novo designed pyrazoline derivatives and pharmacophore generation” The 14th Biennial International Amine Oxidase Workshop, University of Alberta, *Edmonton, CANADA*, July 18th-21st, 2010.
- 7.3.21.** Kemal Yelekçi, “Molecular docking of new MAO A selective pyrazoline derivatives”, The 14th Biennial International Amine Oxidase Workshop, University of Alberta, *Edmonton, CANADA*, July 18th-21st, 2010.
- 7.3.22.** Kemal Yelekçi, “De novo design of selective monoamine oxidase A and B inhibitors: Evaluation of novel pyrazoline derivatives using molecular modeling techniques”, IMPPS-3 Third International Meeting on PHARMACY & PHARMACEUTICAL SCIENCES, June 9-12, 2010, *Istanbul, TURKEY*.
- 7.3.23.** Nesrin Gökhan Kelekçi, Umut Salgın Gökşen, Samiye Yabanoğlu, Gülberk Ucar, Kemal Yelekçi, “Synthesis and selective inhibitory activity against MAO A and B of 3-substituted benzylidenehydrazine derivatives containing 2-benzoxazolinone and molecular docking studies” IMPPS-3 Third International Meeting on PHARMACY & PHARMACEUTICAL SCIENCES, June 9-12, 2010, *Istanbul, TURKEY*.
- 7.3.24.** Seyhan Türkkkan, Safiye Erdem, Kemal Yelekçi, Demet Akten, Nesrin Gökhan, “The effect of active site tyrosine orientation on binding of new pyrazoline derivatives to MAO-B: molecular docking and dynamic simulations”, IMPPS-3 Third International Meeting on

PHARMACY & PHARMACEUTICAL SCIENCES, June 9-12, 2010 , *Istanbul, TURKEY*.

- 7.3.25.** Kemal Yelekçi, “In Silico Design of Novel and Highly Selective Monoamine Oxidase A and Inhibitors: Evaluation of Computational and Experimental Inhibition Values” International Symposium on Drug Research and Development “From Chemistry to Medicine”, May 27-29, 2011, *Antalya, Türkiye*.
- 7.3.26.** E. D. Akdoğan, B. Erman, K. Yelekçi, “In silico design of some novel and highly selective lysine specific histon demethylase inhibitors”, The international Congress on Bioinformatics and Biomics, 18-22 May, 2011, *Kuşadası, İzmir*.
- 7.3.27.** Kemal Yelekçi, “De novo design of lysine specific histon demethylase (LSD1) inhibitors”, Silverman Symposium (tribute to Prof Richard B. Silverman’s 65th birth day), May 13, 2011, Northwestern University, *Evanston, Chicago*.
- 7.3.28.** Kemal Yelekci, “In silico design of novel and highly selective Monoamine oxidase B inhibitors”, 16-18 july: 15th Amine Oxidase Congress AOC2012, *Toulouse, France*.
- 7.3.29.** Umut Salgın-Gökşen, Nesrin Gökhan-Kelekci, Samiye Yabanoglu-Çiftci, Ayse Ercan, Kemal Yelekçi, Gulberk Ucar , “Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives”, 16-18 july, 15th Amine Oxidase Congress AOC2012, *Toulouse, France*.
- 7.3.30.** Kemal Yelekçi, Seyhan Türkkkan, Safiye S. Erdem, Nesrin Gökhan Kelekçi, “Insights into the binding mode of new N-substituted pyrazoline derivatives: docking and quantum chemical calculations”, 16-18 july, 15th Amine Oxidase Congress AOC2012, *Toulouse, France*.
- 7.3.31.** Umut Salgın-Gökşen, Nesrin Gökhan-Kelekçi, Samiye Yabanoglu-Ciftci, Kemal Yelekçi, Gulberk Ucar, “Synthesis, molecular modelling and in vitro screening of monoamine oxidase inhibitory activities of some novel hydazone derivatives”, 16-18 july, 15th Amine Oxidase Congress, AOC2012, *Toulouse, France*.^[SEP]
- 7.3.32.** Begüm Evranos Aksöz, Rahmiye Ertan, Samiye Yabanoğlu, Gülberk Uçar, Kemal Yelekçi “Synthesis and MAO inhibitor activity of some new 4,5-dihydro- 1H-pyrazole and hydrazone derivatives”, 10th International Symposium on pharmaceutical sciences (ISOPS-10), June 26-29, 2012 *Ankara, TURKEY*.
- 7.3.33.** Kemal Yelekçi, (Davetli Konuşmacı) , “Design of selective monoamine oxidase B inhibitors using saffinamide as a scaffold”, CM1103 Action WG Meeting 24-26 November 2012 *Madrid*.
- 7.3.34.** Kemal Yelekci, (Keynote Speaker). “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and its practical application”Summer School: From Computational Enzymology towards Molecular Docking Venue: Main Lecture

room at The National Institute of Chemistry, *Ljubljana/Slovenia*. May 31, 2013.

- 7.3.35.** Serkan Altuntaş, Tuğba Mehmetoğlu, Kemal Yelekçi, 44th World Chemistry Congress, ” (IUPAC 2013) “In silico design of selective monoamine oxidase B inhibitors using indane ring as a scaffold”, 11-16 August, 2013, *Istanbul, TURKEY*.
- 7.3.36.** Tuğba Mehmetoğlu, Serkan Altuntaş, Kemal Yelekçi, 44th World Chemistry Congress” (IUPAC 2013), “In silico design of novel and highly selective Cyclooxygenase-2 inhibitors” 11-16 August, 2013, *Istanbul, TURKEY*.
- 7.3.37.** Kemal YELEKÇİ, A. Bora BÜYÜKTÜRK, Nurdan KAYRAK, Serkan Altuntaş, “In silico design of novel and highly selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2013 RICT- Drug Discovery and Selection, When Chemical Biology meets Drug Design, *Nice, France*, July 3-5, 2013.
- 7.3.38.** Kemal Yelekçi, “In Silico Design of Novel and Selective Neuronal Nitric Oxide Synthase (Nnos) Inhibitors.” CM1103 Action Conference in Malta: Interdisciplinary Chemical Approaches, 22-25.11.2013, Valletta, Malta.
- 7.3.39.** Kemal Yelekçi, “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and Its Practical Application.” Program of Training School COST Action CM1103, 09-13.09.2013, İstanbul.
- 7.3.40.** Kemal Yelekçi, “Novel Synthesis and Molecular Modeling of 3-Substituted Aryl-5-(2-Furanyl)-4,5-Dihydro-(1H)-Pyrazol.” Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases: Dissecting and Modulating Complex Function in the Monoaminergic Systems of the Brain, 22-24.04.2014, Bratislava/Slovakya.
- 7.3.41.** Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan, . “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
- 7.3.42.** Rona R. Ramsay, Thomas Malcomson, A. Ganesan, Sven Mangelinckx, Kemal Yelekci, “Cylopropylamine drugs for LSD1 and MAO: Inactivation of MAO”, 18th International Symposium on Flavins and Flavoproteins, July 27- August 1, 2014, THAILAND.
- 7.3.43.** Kemal Yelekçi, Bahanur Örtmen, “In silico design of potent and selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2nd INTERNATIONAL BAU-DRUG DESIGN SYMPOSIUM Novel Methods and Emerging Targets in Drug Discovery & Patented Drug Development, 17-19 April 2014, Istanbul, Turkey.
- 7.3.44.** Evranos-Aksoz, B.; Yabanoglu-Ciftci, S.; Ucar, G; Kemal Yelekçi . “Synthesis and screening of hMAO inhibitory activities of some new 2-pyrazoline and hydrazone derivatives”, FEBS EMBO 2014 Conference Location: Paris, FRANCE Date: AUG 30-SEP 04, 2014.

- 7.3.45.** Ucar, G; Evranos-Aksoz, B; Yabanoglu-Ciftci, S; Yelekci, Kemal, “Design and synthesis of novel 2-pyrazoline analogues and their hMAO inhibitory activities, 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, : Berlin, GERMANY, JUL 04-09, 2015.
- 7.3.46.** Kemal Yelekçi, “Novel Synthesis and Molecular Modeling of 3-Substituted Aryl-5-(2-Furanyl)-4,5-Dihydro-(1H)-Pyrazol.” Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases: Dissecting and Modulating Complex Function in the Monoaminergic Systems of the Brain, 22-24.04.2014, Bratislava/Slovakya
- 7.3.47.** Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan ,. “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
- 7.3.48.** Rona R. Ramsay, Thomas Malcomson, A. Ganesan, Sven Mangelinckx, Kemal Yelekci, “Cylopropylamine drugs for LSD1 and MAO: Inactivation of MAO”, 18th International Symposium on Flavins and Flavoproteins, July 27- August 1, 2014, THAILAND.
- 7.3.49.** Kemal Yelekçi, Bahanur Örtmen, “In silico design of potent and selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2nd INTERNATIONAL BAU-DRUG DESIGN SYMPOSIUM Novel Methods and Emerging Targets in Drug Discovery & Patented Drug Development, 17-19 April 2014, Istanbul, Turkey.
- 7.3.50.** Evranos-Aksoz, B.; Yabanoglu-Ciftci, S.; Ucar, G; Kemal Yelekçi “Synthesis and screening of hMAO inhibitory activities of some new 2-pyrazoline and hydrazone derivatives”, FEBS EMBO 2014 Conference Location: Paris, FRANCE Date: AUG 30-SEP 04, **2014**.
- 7.3.51.** Yelekçi, K. ve Connaly, J. **2014**. “Homology Modeling of the Human Dopamine Transporter (Hdat): The Elucidation of the Binding Site.” Conference Proceedings EU COST Action CM1103, 8-10 October, Bordeaux, s. 12.
- 7.3.52.** Yelekci, K. ve Djikic, T. **2015**. “De Novo Drug Design for Human Dopamine Transporter.” 3rd International Bau-Drug Design Congress, 1-3 October, İstanbul, s. 33.
- 7.3.53.** Ucar, G; Evranos-Aksoz, B; Yabanoglu-Ciftci, S; Yelekci, Kemal, “Design and synthesis of novel 2-pyrazoline analogues and their hMAO inhibitory activities, 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, : Berlin, GERMANY, JUL 04-09, **2015**.

- 7.3.54. Yelekçi, K. 2015. "Molecular Docking Studies on Hydroxamic Acid Derivatives as Potential Anticancer Agents via Histone." COST-EPIGEN Meeting, 28-30.09.2015, Budapeşte, s. 6.
- 7.3.55. Yelekçi, K. ve Djikic, T. 2015. "In Silico Modeling of Human Dopamine Transporter and Design of Novel Inhibitors." International Multidisciplinary Symposium on Drug Research and Development, Eskişehir, s. 23.
- 7.3.56. Coşkun, P., Yelekci, K., Djikic, T. ve Küçükgülzel, G. 2015. "Synthesis, Characterization Of New Diflunisal 1,2,4-Triazole-3-Thiones. "3rd International BAU-Drug Design Congress, p. 149, 01-03.10.2015, İstanbul.
- 7.3.57. Çoruh, I., Çevik, Ö., Yelekci, K., Djikic, K. ve Küçükgülzel, P. 2015. " Synthesis, Anticancer Activity And Molecular Modeling Of Etodolac-Thioether Derivatives As Potent Methionine Aminopeptidase (Type II) Inhibitors ." 3rd International BAU-Drug Design Congress,p.150, 01-03.10.2015, İstanbul.
- 7.3.58. Evranos, B., Baysal, İ., Ucar, G., Djikic, T. ve Yelekçi, K. 2015. " DESIGN, SYNTHESIS and BIOLOGICAL EVALUATION of MAO-A SELECTIVE NEW 2-PYRAZOLINE and HYDRAZONE DERIVATIVES", International Symposium on Multidisciplinary Drug Design, p. 119, 15-17.10.2015, Eskişehir.
- 7.3.59. Yelekçi, K. ve Djikic, T. "In Silico Modeling of Human Dopamine Transporter and Design of Novel Inhibitors." 51st International Conference on Medicinal Chemistry, 01-03.07.2015, Avignon, s. 141.
- 7.3.60. Gökçen Telli, Umut Salgın Gökşen, Açelya Yalovaç Erikçi, Samiye Yabanoğlu Çiftçi, Banu Cahide Tel, Kemal Yelekçi, Gülberk Uçar, Nesrin Gökhan Keleşçi " ANTIDEPRESSANT ACTIVITY of NOVEL SELECTIVE MONOAMINE OXIDASE-A (MAO-A) INHIBITORS: 2-PYRAZOLINE DERIVATIVES SYNTHESIZED with MOLECULAR MODELLING", International Multidisciplinary Symposium on Drug Research and Development, p. 66, 15-17.10.2015, Eskişehir.
- 7.3.61. **Kemal Yelekci**, Teodora Djikic, "In silico Modeling of Dopamine Transporter and Design of Novel Neuroprotective Agents", 252nd ACS National Meeting in Philadelphia, PA, USA, August 21-25, S. 138, 2016.
- 7.3.62. Kaan Birgül, Abdullah İbrahim Uba, Ozan Çuhadar, Sevgi Koçyiğit Sevinç, Pinar Mega Tiber, Oya Orun, Özgür Yılmaz, **Kemal Yelekçi**, Ş. Güniz Küçükgülzel. Synthesis and Molecular Modeling of New (S)-Naproxen Thioethers as Possible Breast Cancer Agents. 6th International Bahçeşehir University (BAU) Drug Design Congress,

Bahcesehir University School of Medicine, 13-15th December, **2018**, Istanbul, TURKEY.

- 7.3.63.** Birgul, K., Uba, AI, Bekci, H., Cumaoglu, A., Yilmaz, O., **Yelekci, K.**, Kucukguzel, SG. Synthesis and Anticancer Activity of New (S)-Naproxen Derivatives as Methionine Aminopeptidase (Type II) Inhibitors. 12th International Symposium on Pharmaceutical Sciences, 26-29th June, 2018, Ankara, TURKEY.
- 7.3.64. Kemal Yelekci**, Abdullah İbrahim Uba, The search for potential selective inhibitors of human histone deacetylase 6 via pharmacophore-based virtual screening. European Cooperation in Science and Technology (COST) Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, Institut Pasteur, 15th February, 2018, Paris, FRANCE.
- 7.3.65.** Abdullahi İbrahim Uba, **Kemal Yelekci**. Molecular modelling studies on the recently-solved crystal structure of human histone deacetylase 6 catalytic domain 2 complexed with known inhibitors and the design of potential inhibitors for cancer therapy. 5th Multithematic Biomedical Congress (IMBMC), European University, Cyprus 2nd-4th November, 2017, Nicosia, CYPRUS (GREEK CYPRUS)
- 7.3.66.** Abdullahi İbrahim Uba, Kemal Yelekci. Identification of HDAC6 selective inhibitors via structure-based virtual screening and molecular dynamics simulation assay. 5th International Bahçeşehir University (BAU) Drug Design Congress: Recent Developments in Structure- and Ligand-based Drug Design Methodologies, 19th -21st October, 2017, Istanbul, TURKEY
- 7.3.67. Kemal Yelekci**, Abdullahi İbrahim Uba, The search for potential selective inhibitors of human histone deacetylase 6 via pharmacophore-based virtual screening. European Cooperation in Science and Technology (COST) Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting,
- 7.3.68. Kemal Yelekçi**, Abdullahi İ. Uba, “In silico modeling of histone deacetylase enzyme and design of novel inhibitors Computational Chemistry: Application of Molecular Dynamics Simulation and Docking Approaches in Drug Design”. Turkey, Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, **21.03.2018**.
- 7.3.69. Kemal Yelekçi, et al.** “Augmented Virtual-Cross-Match for Donor-Induced Antibody Prediction by Using High Resolution HLA Typing and HLA Epitope Mapping for Better Donor Match”, 12TH EAST-WEST IMMUNOGENETICS CONFERENCE, March, 2018, Prague Czech Republic.
- 7.3.70. Kemal Yelekçi**, “In silico identification of Isoform-Selective HDAC Inhibitors”, EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portugal , September, 2017.

- 7.3.71. Kemal Yelekçi, Abdullahi İ. Uba,** "Molecular modelling studies on the recently-solved crystal structure of human histone deacetylase 6 (HDAC6) catalytic domain 2 complexed with known HDAC inhibitors and the design of potential inhibitors", Cyprus 5th International Bio-Medical Scientific Cyprus Congress, November, 2017.
- 7.3.72. Kemal Yelekçi, et al,** "Epitope Based HLA Matching By Using Antibody Reactivity", 18th Congress of the European Society for Organ Transplantation", Barcelona/Spain, September, 2017.
- 7.3.73. Kemal Yelekçi, Abdullahi İ. Uba,** "Identification of HDAC6 selective inhibitors via structure-based virtual screening and molecular dynamics simulation assay", 5th International BAU Drug Design Congress, Istanbul, October, 2017.
- 7.3.74. Kemal Yelekçi, Abdullahi I. UBA** "In Silico Modeling of Human Dopamine Transporter", The International Symposium on Health Informatics and Bioinformatics, (HIBIT), October 25, Antalya, TURKEY, 2018.
- 7.3.75. Yelekci, Kemal; Uba, Abdullahi** "Intermolecular interactions in human HDAC8 crystal structures and the stability of binding modes of co-crystallized inhibitors", Conference: ACS Fall National Meeting and Exposition Location: San Diego, CA, USA. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Volume: 258 Meeting Abstract: 254 -COMP Published: AUG 25 2019.

7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler:

- 7.4.1.** Katirina Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, Kemal Yelekci and John B. O. Mitchell, Computational approaches for multi-target drug design Drug Design for CNS Diseases: Screening Methodologies, Book Chapter, pp. 18-37, Ramsay, R. R., Di Giovanni, G., eds. (2017). Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases. Lausanne: Frontiers Media. doi: 10.3389/978-2-88945-123-4

7.5. Ulusal hakemli dergilerde yayınlanan makaleler

- 7.5.1.** Kemal Yelekçi, "Two Dimensional FT-NMR Spectroscopy" *Tr. J. Spectroscopy*, 1988, Vol. IX, pp. 1-7.
- 7.5.2.** Kemal Yelekçi, "Assignment of the Individual Protons from the COSY-45 Spectr of 3,6,6- Trimethylbicyclo[3.1.0.]hex-2-ene." *Tr. J. Spectroscopy*, 1988, Vol. IX, pp. 49-57.
- 7.5.3.** Kemal Yelekçi, "€.(Z)-3,5-Dimetil-2,4-Hekzadienoik Asidin Sentezi" *VIII. Kimya ve Kimya Mühendisliği Semp.* 1992, 55-58.
- 7.5.4.** Kemal Yelekçi, "Böcek Feromonları" Hakkı Dursun Yıldız Armağanı, *T.Tarih Kurumu Basımevi*, Ankara, 1995 , 509-521.

7.6. Ulusal bilimsel toplantılarda sunulan ve bildiri kitabında basılan bildiriler

- 7.6.1. Kemal Yelekçi , Kimya-89, IV.Kimya ve Kimya Mühendisliği Sempozyumu. “Alkilidinsiklopentan ve 6,6-Dimetilbisiklo[3.1.0] Hekzanların sentezi ve termal aromatikleştirilmesi”, 9-14 Ekim, 1989 *Kuşadası*.
- 7.6.2. Kemal Yelekçi “Kimya 91, VII.Kimya ve Kimya Mühendisliği Sempozyumu. “2-Asetoksi-2,6,6 trimetilbisiklo[3.1.0] Hekzanın sentezi ve ısıl tepkimesi.”, 2-5 Nisan, 1991 *Gazimağusa, KKTC*.
- 7.6.3. Kemal Yelekçi, Sevim Karataş, Kimya 98 XII. Ulusal Kimya Kongresi “L-DOPA Sentezinde Kullanılacak Substratların Sentezi“, 7-11 Eylül 1998, *Edirne*.
- 7.6.4. Kemal Yelekçi, M. V. Kahraman, Kimya 98 XII. Ulusal Kimya Kongresi , “Monoamin Oksidaz Enzimini İnaktive Eden Amino Eterlerin Sentezi ,“7-11 Eylül 1998, *Edirne*.
- 7.6.5. Kemal Yelekçi, Kimya 99 XIII. Ulusal Kimya Kongresi , “EPR ve ENDOR Spektroskopik Tekniklerin Biyoorganik Kimyada Uygulamaları“, 31 Ağustos-04 Eylül 1999, *Samsun*.
- 7.6.6. Kemal Yelekçi, M.V. Kahraman, S.S. Erdem, Kimya 2000, XIV. Ulusal Kimya Kongresi “Heteroatom İçeren Heptilamin Türevlerinin Sentezi ve MAO B İnaktivasyonuna Etkileri“10-15 Eylül, 2000, *Diyarbakır*.
- 7.6.7. Kemal Yelekçi , Mustafa Toprakçı, “Oksijen İçeren Heptilaminlerin Monoamin Oksidaz Enzimine Bağlanma Afinitilerinin Moleküler Dinamik Hesaplama Yöntemiyle Tahmin Edilmesi”, XVIII. Ulusal Kimya Kongresi, *Kafkas Üniversitesi*, 5-9 Temmuz, 2004 *Kars*.
- 7.6.8. Özlem Karahan, Safiye Erdem ve Kemal Yelekçi, “Monoamin Oksidaz Enziminin Bağlanma Aminleri Tek Elektron Transferi İle Oksitleme Mekanizmasının Hesapsal Yöntemlerle İncelenmesi”, XVIII. Ulusal Kimya Kongresi, *Kafkas Üniversitesi*, 5-9 Temmuz, 2004.
- 7.6.9. Safiye Sağ Erdem, Fahriye Uyar, Özlem Karahan, Kemal Yelekçi, “2-Asetoksi-2,6,6-trimetilbisiklo[3.1.0]hekzan’ın 1,3,3-trimetil-1,4-sikloheksadien’e dönüşme mekanizmasının ab initio ve DFT hesaplamaları”, XIX. Ulusal Kimya Kongresi 30 Eylül – 04 Ekim 2005, Pine Bay Holiday Resort, *Kuşadası , İzmir*.
- 7.6.10. Safiye SAĞ ERDEM *, Kemal YELEKÇİ, “2-Asetoksi-2,6,6-trimetilbisiklo[3.1.0]hekzan’ın termal pirolizi için önerilen biradical mekanizmaların modellenmesi”, XX. Ulusal Kimya Kongresi, 4-8 Eylül 2006.
- 7.6.11. Didem dayangaç-Erden, gamze Bora, peruze Ayhan, Çetin Kocaefe, Sevim Dalkara, Kemal Yelekçi, Ayhan S. Demir, Hayat Erdem-Yurter, “Histon deacetylase inhibition activity and molecular docking of €-resveratrol: its therapeutic potential in spinal muscular atrophy”, XI. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, 28-31 Ekim 2009,

Bodrum, Türkiye. (Prof. Dr. Altan Günalp İkicilik Ödülü'ne layık görülmüştür).

7.6.12. Kemal Yelekçi, “Virüslere Nasıl İlaç Geliştirilir: HIV Virüsü İçin Yapılan Çalışmalar, IV. Ulusal Biyoloji Toplulukları Kongresi, 4-6 Mayıs 2012, Bursa.

7.6.13. Kemal Yelekçi “İlaç Sentezi ve Sektörde İlaç” , 14 Nisan 2012, Türk Kimya Derneği, İstanbul.

7.6.14. Kemal Yelekçi , “In Silico Design of Some Novel and Highly Selective Lysine-Specific Histone Demethylase Inhibitors”, IV. Multidipliner Kanser Araştırma Kongresi, 13 Aralık, 2012, BURSA.

7.6.15. Kemal Yelekçi (Davetli Konuşmacı “ Bilgisayar Destekli İlaç Tasarımı ve Moleküler Modelleme”, Anadolu Üniversitesi, Fen Fakültesi, 20. Yıl Etkinlikleri, 29 Nisan, 2013, Eskişehir.

7.7. Diğer yayınlar

7.7.1. Kemal Yelekçi, Turhan Altınata, “Modern Üniversite Kimyası Problemleri“ *Çağlayan Kitapevi*, Beyoğlu, İstanbul, 1989.

7.7.2. Kemal Yelekçi, “Modern Nükleer Magnetik Rezonans Spektroskopisi ve Uygulamaları“, *Marmara Üniversitesi Teknik Eğt.Fak. Matbaası*, İstanbul,1991, 362 Sayfa.

7.7.3. Mine Enginün, Kemal Yelekçi (Editör), “VIII. Kimya ve Kimya Mühendisliği Sempozyum Kitabı” *Marmara Üniversitesi Yayın* No:518, 1992, 416 Sayfa.

7.7.4. Kemal Yelekçi “Organik Kimya” John McMurry’den Tercüme edildi (Yaklaşık 1200 sayfa).

7.7.5. Doç. Dr. Hunay Evliya, Arş.Gör. Kemal Yelekçi, Arş.Gör. Zeki Necipoğlu, Arş.Gör. Gönül Paksoy, Şermin Gül, “Kromatografi Teknikleri”, *Çukurova Üniversitesi, Fen-Edebiyat Fak. Ders Notu* Seri No:7, ISBN 975-96593-0-1, Haziran 1998.


7.7.6. Spektroskopiye Giriş (Lisans Öğrencileri için, 147 Sayfa).

7.7.7. Organik Madde Yapı Aydınlatılması (Lisans Öğrencileri için, 270 Sayfa).

7.7.8. Stereokimyaya Giriş (Yüksek Lisans Öğrencileri için, 260 Sayfa).

7.7.9. Organik Kimya Laboratuvar Uygulamaları (Lisans Öğrencileri için, 65 Sayfa)

7.8. Uluslararası atıflar



8. Ulusal & Uluslararası Projeler (DPT, TÜBİTAK, AB, vb)

- 8.1. “Radikal Araürünlerin Tespitinde Kullanılan Model Nitron Bileşiklerinin Sentezi” Marmara Üniversitesi Araştırma Fonu: 1993/Fen-8 nolu proje, Prof.Dr. Kemal Yelekçi , M.Vezir Kahraman.
- 8.2. “N-Metilamino Eterlerdeki Oksijen Etkisi, Marmara Üniversitesi Araştırma Fonu: 1998/Fen-3 nolu proje, Prof.Dr. Kemal Yelekçi, M.Vezir Kahraman.
- 8.3. “A New Synthesis Method for L-3,4-Dihidroksifenilalanine by Bakers Yeast”, TUBİTAK: TBAG 1332, Haziran 2000, Prof.Dr. Kemal Yelekçi, Prof. Dr. Haluk Hamamcı, Sevim Karataş, M.Vezir Kahraman.
- 8.4. “Etil-2-Nitro-3-(3,4-Dimetoksi Fenil)-2-Propenoat’ın Sentezi“ Marmara Üniversitesi Araştırma Fonu : 1999/FE-2 nolu proje, Prof.Dr. Kemal Yelekçi.
- 8.5. “Kist Hidatik (Echinococcus Granulosus) Hastalığı İçin Yeni İlaç Tasarımları “Marmara Üniversitesi Araştırma Fonu : 1999/Fen-16 nolu proje, Prof.Dr. Kemal Yelekçi,
- 8.6. “Kist Hidatik (Echinococcus Granulosus) Hastalığının Tedavisinde Kullanılmak, Üzere Mebendazol (5-Benzoil-1H-Benzimidazol-2-il) Metil Ester’in Metil Türevinin Sentezi“, Marmara Üniversitesi Araştırma Fonu : 2000/ FE-5 notlu proje, Prof. Dr. Kemal Yelekçi, Sibel Atalay.
- 8.7. TÜSEB Proje No: 4085 “Kanser Tedavisinde Kullanılmak Üzere Histon Deasetlaz HDAC6 ve HDAC10 Enzimlerine Karşı İn Siliko Tarama ve Medisinal Kimya Yaklaşımlarını Kullanılarak Etkili ve Seçimli Yeni İnhibitörler Geliştirmek”, 2020-2022. (Yürütücü: Devam ediyor).
- 8.8. TÜBİTAK 1001 Proje No: 218S549, “Olası Antikanser Etkili Heteroaril Sülfanil Asetamidler ve Analoglarının Bilgisayar Destekli Tasarımı, Sentezi, Apoptoz, Anjiojenez ve mPEGES-1 Enzim İnhibitörü Etkilerinin İncelenmesi”, 2020-2022 (Araştırmacı: Devam Ediyor).
- 8.9. TÜSEB, Proje desteklenmesine karar verildi, bütçe görüşmeleri devam ediyor. “Meme Kanseri Tedavisine Yönelik Yeni Sentetik Ajanların Geliştirilmesi” (Araştırmacı: Devam Ediyor), 2021-2024



TÜBİTAK-1003. 2015S009 "Development of Novel Synthetic Agents for Prostate Cancer Treatment." Researcher (2016-2020)



COST Action. (CM1406) "Epigenetic Chemical Biology (EPICHEM)". Member. (2015-2018)



FP7. Marie Curie Initial Training Networks (ITN). Call: FP7-PEOPLE-2013-ITN. Project ID: 608381. "Training in Neurodegeneration, Therapeutics Intervention & Neurorepair – TINTIN". Project member. (2013-2017)



İSTKA. "Establishment of Networking between Academia and Drug Companies and organization of a new Technology Center for a novel drug discovery, development and knowledge sharing- [İlaç Temel Araştırma Merkezi – İTAM](#)". Project member. (2012-2013)



COST Action CM1103. "Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain". Member. (2011-2015)



TÜBİTAK-TBAG 211T100. "In Silico Design of Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors in Order to Prevent Neurodegenerative Diseases". Project Director. (2012-2013)



TÜBİTAK 1007 (105G01) . "Drug research and development for hereditary diseases caused by erroneous RNA splicing". Researcher (2006-2009)



FP6-MOBILITY. "Characterisation of Mitochondrial Proteins in Brain". Researcher. (2006-2010)



TÜBİTAK-TBAG 108T232 "Design of new pyrazoline derivatives using molecular modelling; synthesis and determination of their inhibition kinetics by computational and experimental techniques". Principal investigator. (2008-2010)



TÜBİTAK-TBAG 1332 194T033 "Ekmek Mayası (Saccharomyces Cerevisiae) Yardımı ile L-3,4-Dihidroksifenil Alanin (L-Dopa) için Yeni Bir Sentez Yöntemi". Principal investigator.(2000-2004)



TÜBİTAK-TBAG 520 "Melia Azedarach L. (Tesbih ağacı) Meyvelerinin Özütlerinden İzole Edilen Etkin Maddeler ve Pamuk Zararlıları Üzerine Etkileri". Investigator. (1983-1986)

9. İdari Görevler

9.1. EGE ÜNİVERSİTESİ

9.1.1. Bölüm Başkan Yardımcısı (Ege Üniversitesi, Fen Fakültesi, Kimya Bölümü, Bornova-İZMİR), 8.9.1988-.10.1989.

9.2. MARMARA ÜNİVERSİTESİ, FEN EDEBİYAT FAKÜLTESİ

9.2.1. Dekan Yardımcısı, 15.8.1991-31.12.1992.

9.2.2. Kimya Bölüm Başkan Yardımcısı 28.09.1994- 10.03. 1998.

9.2.3. Kimya Bölüm Başkanı 11.03.1988- 15.11.2000

9.2.4. Döner Sermaye İşletme Müdürü 1.01.1992- 1995.

9.2.5. Organik Kimya Anabilim Dalı Başkanı 20.09.1994-01.11.2000.

9.2.6. Fen Edebiyat Fakültesi DEKANI 15.09.1998- 16.07.2001

9.3. KADİR HAS ÜNİVERSİTESİ, FEN EDEBİYAT FAKÜLTESİ

9.3.1. Rektör Yardımcısı (17.07.2001- 18.12.2003).

9.3.2. Fen Edebiyat Fakültesi DEKANI (17.07.2001- 01.03.2006).

9.3.3. Fen Bilimleri Enstitüsü Müdürlüğü (2004- 01.03.2006).

9.3.4. Mühendislik ve Doğa Bilimleri Fakültesi (Fakülte Kurulu ve Yönetim Kurulu üyeliği).

9.3.5. Biyoinformatik ve Genetik Bölüm Başkanlığı (2012-halen).

10. Bilimsel ve Mesleki Kuruluşlara Üyelikler

10.1. Türk Kimya Derneği Üyesi

10.2. ODTÜ İstanbul Mezunlar Derneği Üyesi

10.3. Amerikan Kimya Derneği Üyesi (ACS)

11. Ödüller

11.1. NATO (Araştırma Projesi, 1995-1997)

11.2. NIH (National Institutes of Health) bursu (doktora sonrası çalışma için).

11.3. FULBRIGHT Bursu (Amerika Birleşik Devletleri'nde doktora yapmak için).

11.4. DAAD Bursu (Goethe Enstitüsü'nde Almanca öğrenmek için).

11.5. Yüksek Şeref Öğrencisi (Üniversite 4.sınıf).

11.6. Şeref Öğrencisi (Üniversite 3.sınıf).

11.7. 2008 Yılı Novartis Farmasötik ve Medisinal Kimya İlaç Tasarım ve Geliştirme Ödülü.

11.8. Kadir Has Üniversitesi, Akademik Ödül, 2014.

12. Son iki yılda verdiğiniz lisans ve lisansüstü düzeydeki dersler için aşağıdaki tabloyu doldurunuz.

Akademik Yıl	Dönem	Dersin Adı	Haftalık Saati		Öğrenci Sayısı
			T	U	
2020-2021	Güz	Organic Chemistry I	3		30
		Pharmacophor Modeling	3		25
		Introduction to Bioinformatics (Yüksek Lisans)	3		12
		Advanced Bioinformatics (Doktora)	3		4

	Bahar	Organic Chemistry of Drug Design and Drug Action (Yüksek Lisans)	3		12
		Organic Chemistry II	3	2	30
2021-2022	Güz	Biology II	3		20
		Organic Chemistry I	3		32
	Bahar	Organic Chemistry of Drug Design and Drug Action (Yüksek Lisans)	3	-	
		Organic Chemistry II	3	2	30